Celgene Archives - DelveInsight

Celgene

Rare diseases challenges | Rare diseases clinical trials, incidence, and funding
The Paradox of Rare: Chalking out Challenges in the Rare Disease Market

How is a Rare disease defined? Well, it depends on the geography in question, since there is no universal definition, even so, the definition revolves around the point of prevalence or incidence o...


Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval
Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval

Bristol-Meyers Squibb and Acceleron Pharma have announced that US FDA committee will review BMS’s supplemental Biologics License Application (sBLA) for its Reblozyl in MDS.Reblozyl ((luspater...


Johnson & Johnson
Notizia

If dementia genes are found, drug discovery can be accelerated in brain disorders The overproduction of a protein called tau has been detected in the neuron degeneration that causes Alzheimer’s and...


Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates; Celgene’s deal

Preclinical biotech Synthorx needs a USD 100 Million IPO The early-stage Synthorx needs USD 100 million IPO.  A while ago, La Jolla, California-based biotech got off a USD 63 million series C, but ...


Therapeutics
Business Cocktail

Sanofi bags rights to Revolution’s SHP2 cancer drug Sanofi has paid $50 million to work with Revolution Medicines on the development of cancer drugs against SHP2. The partners plan to move small mo...


cancer
Key Clinical Outcomes- 30/07/2018

AbbVie’s Orilissa for Endometriosis Pain Management Receives FDA ApprovalAbbVie in cooperation with Neurocrine Biosciences announced that the U.S. FDA approved Orilissa (elagolix), the first a...


transthyretin amyloidosis
Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set...

Atara Biotherapeutics hires ex-Genentech SVP to lead its global R&D program Atara Biotherapeutics recently hired Dietmar Berger, M.D., Ph.D., as its R&D global head. During the time in Gene...


Default Blog Image
Snippet: M&A activities of big pharma’s will fuel CAR-T cell therapy

Gilead Sciences Inc. bought Kite Pharma (USD 11.9 Billion) while Celgene took over Juno Therapeutics (USD 9 Billion) to make the greatest speculation into this rising subject over the recent one ...


transthyretin amyloidosis
CRISPR to cure sickle cell; FDA rejected; Stem cells use; Celgene spinoff

Rice University researchers tested CRISPR to cure sickle cell, now preparing for upcoming challenges A team of Researchers led by Rice University has recently tested CRISPR to correct the sickle ce...


BioGen
Business Cocktail

Roivant expanding its horizon into metabolic diseases segment with USD 650 million diabetes pact with Poxel Roivant Sciences has recently signed a USD 650 million deal to acquire near-glo...


Editor's Pick
An in-depth Assessment of the Top Drugs Launched by Leading Global Companies ...

Progress is driven by innovation. When it comes to developing novel medications and the...

Changing Dynamics of HIV-1 Treatment Market

The HIV-1 treatment market for naïve and experienced patients is evolving consistently....

Which Countries Top the Chart in Global Pharmaceutical Market?

The Pharmaceuticals segment of the Healthcare Industry has a significant market across ...

von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!

Von Willebrand disease is a type of blood disorder that causes the blood to clot improp...

Analyzing the Key Companies and the Emerging Gene Therapy in the Dermatology ...

Advances in genetics research have sparked a surge in interest in gene therapy in derma...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.